BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel) 2021;9:3. [PMID: 33498356 DOI: 10.3390/medsci9010003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Abramson HN. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. IJMS 2023;24:2645. [DOI: 10.3390/ijms24032645] [Reference Citation Analysis]
2 Noori M, Fayyaz F, Rezaei N. Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis. Expert Rev Anticancer Ther 2023;:1-12. [PMID: 36638778 DOI: 10.1080/14737140.2023.2169139] [Reference Citation Analysis]
3 Plano F, Corsale AM, Gigliotta E, Camarda G, Vullo C, Di Simone M, Shekarkar Azgomi M, Speciale M, Carlisi M, Caccamo N, Dieli F, Meraviglia S, Siragusa S, Botta C. Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again. Hematol Rep 2023;15:23-49. [PMID: 36648882 DOI: 10.3390/hematolrep15010004] [Reference Citation Analysis]
4 A. Al-anazi K. Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies. Recent Update on Multiple Myeloma [Working Title] 2023. [DOI: 10.5772/intechopen.109279] [Reference Citation Analysis]
5 A. Al-anazi K, Alshaibani Z, Kalogianidis P. An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma. Recent Update on Multiple Myeloma [Working Title] 2023. [DOI: 10.5772/intechopen.109059] [Reference Citation Analysis]
6 De Novellis D, Fontana R, Giudice V, Serio B, Selleri C. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance. Int J Mol Sci 2022;24. [PMID: 36614086 DOI: 10.3390/ijms24010645] [Reference Citation Analysis]
7 Wang Z, Chen C, Wang L, Jia Y, Qin Y. Chimeric antigen receptor T-cell therapy for multiple myeloma. Front Immunol 2022;13:1050522. [PMID: 36618390 DOI: 10.3389/fimmu.2022.1050522] [Reference Citation Analysis]
8 Chen M, Zhu J, Yang X, Yao J, Liu Y, Liu Q. PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients. Eur J Med Res 2022;27:296. [PMID: 36529769 DOI: 10.1186/s40001-022-00923-5] [Reference Citation Analysis]
9 Gatopoulou X, Iraqi W, Morgan K, Helme K, Spain VA, Redfearn J, Gardiner B. The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings. Clinicoecon Outcomes Res 2022;14:731-53. [PMID: 36569430 DOI: 10.2147/CEOR.S367458] [Reference Citation Analysis]
10 Eibodeng GO, Fatola A, Galeas J. A case of incidental multiple Myeloma presenting with pathologically proven large frontal skull plasmacytoma and review of therapeutic targets: Case report. J Case Rep Images Oncology 2022;8:50-55. [DOI: 10.5348/100116z10gi2022cr] [Reference Citation Analysis]
11 Łuczkowska K, Kulig P, Baumert B, Machaliński B. The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib. Nutrients 2022;14. [PMID: 36501221 DOI: 10.3390/nu14235190] [Reference Citation Analysis]
12 Ghanem B, Shi L. Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US. Clin Drug Investig 2022;42:1085-1092. [DOI: 10.1007/s40261-022-01215-w] [Reference Citation Analysis]
13 Iula R, De Novellis D, Trastulli F, Della Pepa R, Fontana R, Carobene A, Di Perna M, D’ambrosio A, Romano M, Leone A, De Fazio L, Fiumarella A, Gaeta G, Marafioti V, Barbato S, Palmieri S, Rocco S, Serio B, Califano C, Pane F, Ferrara F, Giudice V, Selleri C, Catalano L. Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1026251] [Reference Citation Analysis]
14 Mikulski D, Robak P, Ryżewska W, Stańczak K, Kościelny K, Góra-tybor J, Robak T. Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. JCM 2022;11:5908. [DOI: 10.3390/jcm11195908] [Reference Citation Analysis]
15 Dadzie TG, Green AC. The role of the bone microenvironment in regulating myeloma residual disease and treatment. Front Oncol 2022;12:999939. [DOI: 10.3389/fonc.2022.999939] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Bernstein ZS, Kim EB, Raje N. Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. Cells 2022;11:2308. [DOI: 10.3390/cells11152308] [Reference Citation Analysis]
17 Derudas D, Concu C. Management of Renal Failure in Multiple Myeloma. Recent Update on Multiple Myeloma [Working Title] 2022. [DOI: 10.5772/intechopen.105444] [Reference Citation Analysis]
18 Silberstein AE, Fiala MA, Loh KP, Cordner T, Mian H, Wildes TM. A prospective study of adherence to lenalidomide for multiple myeloma using Medication Event Monitoring System (MEMS) caps.. [DOI: 10.1101/2022.05.30.22275780] [Reference Citation Analysis]
19 Cepeda-piorno F, González-garcía E, Méndez-gallego A, Torres-varona J, García-moreira V, Sordo-bahamonde C, Alberdigarcía-del-castillo C, Astobieta-madariaga E, Mateos-manteca M, González-rodríguez S, Beksac M. Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma. Advances in Hematology 2022;2022:1-7. [DOI: 10.1155/2022/4282226] [Reference Citation Analysis]
20 Gilchrist A, Echeverria SL. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma. Front Endocrinol (Lausanne) 2022;13:846310. [PMID: 35399952 DOI: 10.3389/fendo.2022.846310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Park H, Lee S, Lee J, Pak J, Lee K, Lee S, Jung J. Detecting Multiple Myeloma Infiltration of the Bone Marrow on CT Scans in Patients with Osteopenia: Feasibility of Radiomics Analysis. Diagnostics 2022;12:923. [DOI: 10.3390/diagnostics12040923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Morè S, Corvatta L, Manieri VM, Saraceni F, Scortechini I, Mancini G, Fiorentini A, Olivieri A, Offidani M. Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go? Cells 2022;11:606. [DOI: 10.3390/cells11040606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Paing MP, Sento A, Bui TH, Pintavirooj C. Instance Segmentation of Multiple Myeloma Cells Using Deep-Wise Data Augmentation and Mask R-CNN. Entropy 2022;24:134. [DOI: 10.3390/e24010134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Abraham E, Trainor N, Ostrout N, Hewitt MM. Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt. Current Opinion in Biomedical Engineering 2021;20:100340. [DOI: 10.1016/j.cobme.2021.100340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Borsi E, Serban CL, Potre C, Potre O, Putnoky S, Samfireag M, Tudor R, Ionita I, Ionita H. High Carbohydrate Diet Is Associated with Severe Clinical Indicators, but Not with Nutrition Knowledge Score in Patients with Multiple Myeloma. Int J Environ Res Public Health 2021;18:5444. [PMID: 34069672 DOI: 10.3390/ijerph18105444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Innao V, Allegra A, Ginaldi L, Pioggia G, De Martinis M, Musolino C, Gangemi S. Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies. Int J Mol Sci 2021;22:4922. [PMID: 34066482 DOI: 10.3390/ijms22094922] [Reference Citation Analysis]
27 Murkamilov I, Aitbaev K, Kudaibergenova I, Fomin V, Murkamilova Z, Yusupov F. Multiple Myeloma and Comorbidal Diseases in the Practice of a Doctor: A Literature Review and a Clinical Case Description. BSP 2021;7:186-211. [DOI: 10.33619/2414-2948/65/22] [Reference Citation Analysis]
28 Krstevska Balkanov S, Trajkova S, Genadieva Stavric S, Pivkova Veljanovska A, Popova Labacevska M, Spasovski D, Rambabova Bushljetik I, Kalcev G, Panovska Stavridis I. Myeloma multiplex treatment and overall survival. Maced Pharm Bull 2022;67:79-90. [DOI: 10.33320/10.33320/maced.pharm.bull.2021.67.01.008] [Reference Citation Analysis]